person · Reporting owner

MIGNONE ROBERTO

Disclosed activity across 4 companies

Tapewire entity: 20298
SEC CIK: 0001258394

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Avanti Acquisition Corp.AVAN · Entity 146146	Director	October 01, 2020	October 05, 2020
Guardant Health, Inc.GH · Entity 3238	Director	September 21, 2026	September 22, 2026
TEVA PHARMACEUTICAL INDUSTRIES LTDTEVA · Entity 3063	Director	September 19, 2026	September 22, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Avanti Acquisition Corp.

Report date October 01, 2020 · Filed October 05, 2020

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Units, consisting of Class A ordinary share and one-half ofSEC Table I · non-derivative	IndirectSee Footnote	1,000,000	Reported balance After 2020-10-01 transaction · row 1 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 1 · 2020-10-01 · Purchase · Acquired 1,000,000 · Balance 1,000,000 F1: The units disclosed in Table I were purchased in the Issuer's initial public offering. Such units of this Form 4 are held of record by Swiftcurrent Partners, L.P. and Swiftcurrent Offshore Master, Ltd. (the "Funds"). Bridger Management, LLC is the investment adviser to the Funds and Mr. Mignone is the manager of Bridger Management, LLC. By reason of the provisions of Rule 16a-1(a)(1) under the Securities Exchange Act of 1934, as amended, Mr. Mignone may be deemed to beneficially own the units held of record by the Funds. Mr. Mignone disclaims beneficial ownership of the units held of record by the Funds except to the extent of his indirect pecuniary interest therein and this report shall not be deemed an admission that Mr. Mignone is the beneficial owner of the units held of record by the Funds for purposes of Section 16, or for any other purpose.

Filing footnotes · ownership attribution and instrument terms

F1: The units disclosed in Table I were purchased in the Issuer's initial public offering. Such units of this Form 4 are held of record by Swiftcurrent Partners, L.P. and Swiftcurrent Offshore Master, Ltd. (the "Funds"). Bridger Management, LLC is the investment adviser to the Funds and Mr. Mignone is the manager of Bridger Management, LLC. By reason of the provisions of Rule 16a-1(a)(1) under the Securities Exchange Act of 1934, as amended, Mr. Mignone may be deemed to beneficially own the units held of record by the Funds. Mr. Mignone disclaims beneficial ownership of the units held of record by the Funds except to the extent of his indirect pecuniary interest therein and this report shall not be deemed an admission that Mr. Mignone is the beneficial owner of the units held of record by the Funds for purposes of Section 16, or for any other purpose.

Guardant Health, Inc.

Report date September 21, 2026 · Filed September 22, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	10,274	Reported balance After 2026-09-21 transaction · row 1 1 source row Row 1 · 2026-09-21 · Exercise / conversion · Acquired 264 · Balance 10,274
Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00	Direct	6,600	Reported balance After 2026-09-21 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2026-09-21 · Exercise / conversion · Disposed 264 · Balance 6,600 F1: The restricted stock unit award granted on November 8, 2024 vests over a four-year period. 25% of the shares subject to such award vested on October 21, 2025 and the remaining 75% vests monthly for the three-year period thereafter. F2: Not applicable for Restricted Stock Units.

Filing footnotes · ownership attribution and instrument terms

F1: The restricted stock unit award granted on November 8, 2024 vests over a four-year period. 25% of the shares subject to such award vested on October 21, 2025 and the remaining 75% vests monthly for the three-year period thereafter.

F2: Not applicable for Restricted Stock Units.

TEVA PHARMACEUTICAL INDUSTRIES LTD

Report date September 19, 2026 · Filed September 22, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Ordinary SharesSEC Table I · non-derivative	Indirect[see footnote]	0	Reported balance After 2026-09-18 transaction · row 1 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 1 · 2026-09-18 · Sale · Disposed 367,600 · Balance 0 F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.68 to $39.38, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. F2: The 367,600 Ordinary Shares disclosed in Table I of this Form 4 were held of record by Swiftcurrent Master Fund Ltd. (the "Fund"). Bridger Management, LLC is the investment adviser to the Fund and Mr. Mignone is the manager of Bridger Management, LLC. By reason of the provisions of Rule 16a-1(a)(1) under the Securities Exchange Act of 1934, as amended, Mr. Mignone was deemed to beneficially own the Ordinary Shares held of record by the Fund. Mr. Mignone disclaimed beneficial ownership of the Ordinary Shares held of record by the Fund except to the extent of his indirect pecuniary interest therein and this report shall not be deemed an admission that Mr. Mignone was the beneficial owner of the Ordinary Shares held of record by the Fund for purposes of Section 16, or for any other purpose.
Ordinary SharesSEC Table I · non-derivative	Direct	119,807	Reported balance Holding disclosure · report date 2026-09-19 · row 2 Holding and transaction disclosures are not merged. 1 source row Row 2 · Balance 119,807

Filing footnotes · ownership attribution and instrument terms

F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.68 to $39.38, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.

F2: The 367,600 Ordinary Shares disclosed in Table I of this Form 4 were held of record by Swiftcurrent Master Fund Ltd. (the "Fund"). Bridger Management, LLC is the investment adviser to the Fund and Mr. Mignone is the manager of Bridger Management, LLC. By reason of the provisions of Rule 16a-1(a)(1) under the Securities Exchange Act of 1934, as amended, Mr. Mignone was deemed to beneficially own the Ordinary Shares held of record by the Fund. Mr. Mignone disclaimed beneficial ownership of the Ordinary Shares held of record by the Fund except to the extent of his indirect pecuniary interest therein and this report shall not be deemed an admission that Mr. Mignone was the beneficial owner of the Ordinary Shares held of record by the Fund for purposes of Section 16, or for any other purpose.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Cardiff Oncology, Inc.

Report date November 11, 2016 · Filed November 15, 2016

Jointly reported with BRIDGER MANAGEMENT, LLC

Section 16 reporting ended · disclosed 2016-11-15. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common Stock, $.0001 par value per shareSEC Table I · non-derivative	IndirectSee footnotes	2,968,115	Reported balance After 2016-11-11 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2016-11-11 · Purchase · Disposed 322,472 · Balance 2,968,115 F1: The price reported in Column 4 is a weighted average price, rounded to the nearest whole cent. These Shares (as defined below) were sold in multiple transactions at prices ranging from $3.00 to $3.38, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, full information regarding the number of Shares sold at each separate price within the ranges set forth in footnote (1) to this Form 4. F2: The shares of Common Stock, $.0001 par value per share (the "Shares"), reported herein as indirectly beneficially owned by the Reporting Persons are held of record by Swiftcurrent Partners, L.P., Swiftcurrent Offshore Master Ltd. and Bridger Healthcare Ltd. Bridger Management LLC is the investment adviser to Swiftcurrent Partners L.P., Swiftcurrent Offshore Master Ltd., and Bridger Healthcare Ltd., and as such, may be deemed to share beneficial ownership of the Shares. Roberto Mignone is the manager of Bridger Management, LLC. F3: Each reporting person and entity named herein disclaims beneficial ownership of the reported securities except to the extent of his or its pecuniary interest therein and this report shall not be deemed an admission that the reporting person or any entity named herein is the beneficial owner of the securities for purposes of Section 16, or for any other purpose.

Filing footnotes · ownership attribution and instrument terms

F1: The price reported in Column 4 is a weighted average price, rounded to the nearest whole cent. These Shares (as defined below) were sold in multiple transactions at prices ranging from $3.00 to $3.38, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, full information regarding the number of Shares sold at each separate price within the ranges set forth in footnote (1) to this Form 4.

F2: The shares of Common Stock, $.0001 par value per share (the "Shares"), reported herein as indirectly beneficially owned by the Reporting Persons are held of record by Swiftcurrent Partners, L.P., Swiftcurrent Offshore Master Ltd. and Bridger Healthcare Ltd. Bridger Management LLC is the investment adviser to Swiftcurrent Partners L.P., Swiftcurrent Offshore Master Ltd., and Bridger Healthcare Ltd., and as such, may be deemed to share beneficial ownership of the Shares. Roberto Mignone is the manager of Bridger Management, LLC.

F3: Each reporting person and entity named herein disclaims beneficial ownership of the reported securities except to the extent of his or its pecuniary interest therein and this report shall not be deemed an admission that the reporting person or any entity named herein is the beneficial owner of the securities for purposes of Section 16, or for any other purpose.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
June 14, 2022 Filed Jun 16, 2022 11:39 UTC	TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063	Exercise / conversionRestricted Share Units · Derivative	14,479	$0.00	$0.00	Disclosure SEC source: 0001209191-22-037249 · doc4.xml · derivative · entry 3 MIGNONE ROBERTO · CIK 0001258394 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 14,479 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F4 · derivative.exercise_date: Restricted share units were granted on June 14, 2021 and vested on June 14, 2022. F4 · derivative.expiration_date: Restricted share units were granted on June 14, 2021 and vested on June 14, 2022. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document
June 14, 2022 Filed Jun 16, 2022 11:39 UTC	TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063	Exercise / conversionOrdinary Shares	14,479	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-22-037249 · doc4.xml · nonDerivative · entry 1 MIGNONE ROBERTO · CIK 0001258394 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,765 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document
June 14, 2021 Filed Jun 16, 2021 12:20 UTC	TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063	GrantRestricted Share Units · Derivative	14,479	$0.00	$0.00	Disclosure SEC source: 0001209191-21-040811 · doc4.xml · derivative · entry 1 MIGNONE ROBERTO · CIK 0001258394 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,479 Underlying: Ordinary Shares · 14,479 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F2 · derivative.exercise_date: Restricted share units were granted on June 14, 2021 and vest on June 14, 2022. F2 · derivative.expiration_date: Restricted share units were granted on June 14, 2021 and vest on June 14, 2022. F3 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document
June 09, 2021 Filed Jun 10, 2021 11:43 UTC	TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063	Exercise / conversionRestricted Share Units · Derivative	12,668	$0.00	$0.00	Disclosure SEC source: 0001209191-21-039372 · doc4.xml · derivative · entry 3 MIGNONE ROBERTO · CIK 0001258394 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 12,668 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F4 · derivative.exercise_date: Restricted share units were granted on June 9, 2020 and vested on June 9, 2021. F4 · derivative.expiration_date: Restricted share units were granted on June 9, 2020 and vested on June 9, 2021. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document
June 09, 2021 Filed Jun 10, 2021 11:43 UTC	TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063	Exercise / conversionOrdinary Shares	12,668	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-21-039372 · doc4.xml · nonDerivative · entry 1 MIGNONE ROBERTO · CIK 0001258394 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,286 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document
June 05, 2021 Filed Jun 8, 2021 11:29 UTC	TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063	Exercise / conversionRestricted Share Units · Derivative	6,041	$0.00	$0.00	Disclosure SEC source: 0001209191-21-038816 · doc4.xml · derivative · entry 3 MIGNONE ROBERTO · CIK 0001258394 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 6,041 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F4 · derivative.exercise_date: Restricted share units were granted on June 5, 2018 and vested on June 5, 2021. F4 · derivative.expiration_date: Restricted share units were granted on June 5, 2018 and vested on June 5, 2021. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document
June 05, 2021 Filed Jun 8, 2021 11:29 UTC	TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063	Exercise / conversionOrdinary Shares	6,041	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-21-038816 · doc4.xml · nonDerivative · entry 1 MIGNONE ROBERTO · CIK 0001258394 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,618 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document
October 01, 2020 Filed Oct 5, 2020 21:09 UTC	Avanti Acquisition Corp. AVAN · Entity 146146	PurchaseUnits, consisting of Class A ordinary share and one-half of	1,000,000	$10.00	$10,000,000.00	Disclosure SEC source: 0000899243-20-027310 · doc4.xml · nonDerivative · entry 1 MIGNONE ROBERTO · CIK 0001258394 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 1,000,000 F1 · kind: The units disclosed in Table I were purchased in the Issuer's initial public offering. Such units of this Form 4 are held of record by Swiftcurrent Partners, L.P. and Swiftcurrent Offshore Master, Ltd. (the "Funds"). Bridger Management, LLC is the investment adviser to the Funds and Mr. Mignone is the manager of Bridger Management, LLC. By reason of the provisions of Rule 16a-1(a)(1) under the Securities Exchange Act of 1934, as amended, Mr. Mignone may be deemed to beneficially own the units held of record by the Funds. Mr. Mignone disclaims beneficial ownership of the units held of record by the Funds except to the extent of his indirect pecuniary interest therein and this report shall not be deemed an admission that Mr. Mignone is the beneficial owner of the units held of record by the Funds for purposes of Section 16, or for any other purpose. F1 · ownership.nature: The units disclosed in Table I were purchased in the Issuer's initial public offering. Such units of this Form 4 are held of record by Swiftcurrent Partners, L.P. and Swiftcurrent Offshore Master, Ltd. (the "Funds"). Bridger Management, LLC is the investment adviser to the Funds and Mr. Mignone is the manager of Bridger Management, LLC. By reason of the provisions of Rule 16a-1(a)(1) under the Securities Exchange Act of 1934, as amended, Mr. Mignone may be deemed to beneficially own the units held of record by the Funds. Mr. Mignone disclaims beneficial ownership of the units held of record by the Funds except to the extent of his indirect pecuniary interest therein and this report shall not be deemed an admission that Mr. Mignone is the beneficial owner of the units held of record by the Funds for purposes of Section 16, or for any other purpose. Read SEC document
August 11, 2020 Filed Aug 13, 2020 20:13 UTC	TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063	Exercise / conversionRestricted Share Units · Derivative	7,956	$0.00	$0.00	Disclosure SEC source: 0001209191-20-046593 · doc4.xml · derivative · entry 3 MIGNONE ROBERTO · CIK 0001258394 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 7,956 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F4 · derivative.exercise_date: Restricted share units were granted on August 11, 2017 and vested on August 11, 2020. F4 · derivative.expiration_date: Restricted share units were granted on August 11, 2017 and vested on August 11, 2020. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document
August 11, 2020 Filed Aug 13, 2020 20:13 UTC	TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063	Exercise / conversionOrdinary Shares	7,956	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-20-046593 · doc4.xml · nonDerivative · entry 1 MIGNONE ROBERTO · CIK 0001258394 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,577 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document
June 11, 2020 Filed Jun 15, 2020 11:35 UTC	TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063	Exercise / conversionRestricted Share Units · Derivative	17,621	$0.00	$0.00	Disclosure SEC source: 0001209191-20-036499 · doc4.xml · derivative · entry 3 MIGNONE ROBERTO · CIK 0001258394 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 17,621 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F4 · derivative.exercise_date: Restricted share units were granted on June 11, 2019 and vested on June 11, 2020. F4 · derivative.expiration_date: Restricted share units were granted on June 11, 2019 and vested on June 11, 2020. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document
June 11, 2020 Filed Jun 15, 2020 11:35 UTC	TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063	Exercise / conversionOrdinary Shares	17,621	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-20-036499 · doc4.xml · nonDerivative · entry 1 MIGNONE ROBERTO · CIK 0001258394 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,621 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document
June 09, 2020 Filed Jun 11, 2020 11:13 UTC	TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063	GrantRestricted Share Units · Derivative	12,668	$0.00	$0.00	Disclosure SEC source: 0001209191-20-035785 · doc4.xml · derivative · entry 1 MIGNONE ROBERTO · CIK 0001258394 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,668 Underlying: Ordinary Shares · 12,668 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F2 · derivative.exercise_date: Restricted share units were granted on June 9, 2020 and vest on June 9, 2021. F2 · derivative.expiration_date: Restricted share units were granted on June 9, 2020 and vest on June 9, 2021. F3 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document
June 11, 2019 Filed Jun 13, 2019 10:26 UTC	TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063	GrantRestricted Share Units · Derivative	17,621	$0.00	$0.00	Disclosure SEC source: 0001209191-19-036590 · doc4.xml · derivative · entry 1 MIGNONE ROBERTO · CIK 0001258394 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,621 Underlying: Ordinary Shares · 17,621 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F2 · derivative.exercise_date: Restricted share units were granted on June 11, 2019 and vest on June 11, 2020. F2 · derivative.expiration_date: Restricted share units were granted on June 11, 2019 and vest on June 11, 2020. F3 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document
June 05, 2018 Filed Jun 7, 2018 10:46 UTC	TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063	GrantRestricted Share Units · Derivative	6,041	$0.00	$0.00	Disclosure SEC source: 0001209191-18-036197 · doc4.xml · derivative · entry 1 MIGNONE ROBERTO · CIK 0001258394 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,041 Underlying: Ordinary Shares · 6,041 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F2 · derivative.exercise_date: Restricted share units were granted on June 5, 2018 and vest on June 5, 2021. F2 · derivative.expiration_date: Restricted share units were granted on June 5, 2018 and vest on June 5, 2021. F3 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document
May 10, 2018 Filed May 11, 2018 20:15 UTC	TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063	PurchaseOrdinary Shares	250,000	$19.32	$4,829,700.00	Disclosure SEC source: 0001209191-18-029534 · doc4.xml · nonDerivative · entry 2 MIGNONE ROBERTO · CIK 0001258394 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · [see footnote] Disclosed balance after: 1,500,000 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F4 · price: The price reported in Column 4 is a weighted average price. These Ordinary Shares were purchased in multiple transactions at prices ranging from $19.2450 to $19.3700, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of Ordinary Shares purchased at each separate price. F3 · ownership.nature: The 1,500,000 Ordinary Shares disclosed in Table I of this Form 4 are held of record by Swiftcurrent Partners, L.P. and Swiftcurrent Offshore Master, Ltd. (the "Funds"). Bridger Management, LLC is the investment adviser to the Funds and Mr. Mignone is the manager of Bridger Management, LLC. By reason of the provisions of Rule 16a-1(a)(1) under the Securities Exchange Act of 1934, as amended, Mr. Mignone may be deemed to beneficially own the Ordinary Shares held of record by the Funds. Mr. Mignone disclaims beneficial ownership of the Ordinary Shares held of record by the Funds except to the extent of his indirect pecuniary interest therein and this report shall not be deemed an admission that Mr. Mignone is the beneficial owner of the Ordinary Shares held of record by the Funds for purposes of Section 16, or for any other purpose. Read SEC document
May 09, 2018 Filed May 11, 2018 20:15 UTC	TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063	PurchaseOrdinary Shares	500,000	$19.21	$9,603,150.00	Disclosure SEC source: 0001209191-18-029534 · doc4.xml · nonDerivative · entry 1 MIGNONE ROBERTO · CIK 0001258394 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · [see footnote] Disclosed balance after: 1,250,000 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: The price reported in Column 4 is a weighted average price. These Ordinary Shares were purchased in multiple transactions at prices ranging from $18.99 to $19.30, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of Ordinary Shares purchased at each separate price. F3 · ownership.nature: The 1,500,000 Ordinary Shares disclosed in Table I of this Form 4 are held of record by Swiftcurrent Partners, L.P. and Swiftcurrent Offshore Master, Ltd. (the "Funds"). Bridger Management, LLC is the investment adviser to the Funds and Mr. Mignone is the manager of Bridger Management, LLC. By reason of the provisions of Rule 16a-1(a)(1) under the Securities Exchange Act of 1934, as amended, Mr. Mignone may be deemed to beneficially own the Ordinary Shares held of record by the Funds. Mr. Mignone disclaims beneficial ownership of the Ordinary Shares held of record by the Funds except to the extent of his indirect pecuniary interest therein and this report shall not be deemed an admission that Mr. Mignone is the beneficial owner of the Ordinary Shares held of record by the Funds for purposes of Section 16, or for any other purpose. Read SEC document
November 11, 2016 Filed Nov 15, 2016 19:29 UTC	Cardiff Oncology, Inc. TROV · Entity 6917	PurchaseCommon Stock, $.0001 par value per share	322,472	$3.08	$993,213.76	Disclosure SEC source: 0001140361-16-086749 · doc1.xml · nonDerivative · entry 1 BRIDGER MANAGEMENT, LLC · CIK 0001166309 · Former 10% Owner MIGNONE ROBERTO · CIK 0001258394 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: 2,968,115 F1 · price: The price reported in Column 4 is a weighted average price, rounded to the nearest whole cent. These Shares (as defined below) were sold in multiple transactions at prices ranging from $3.00 to $3.38, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, full information regarding the number of Shares sold at each separate price within the ranges set forth in footnote (1) to this Form 4. F2 · ownership.direct: The shares of Common Stock, $.0001 par value per share (the "Shares"), reported herein as indirectly beneficially owned by the Reporting Persons are held of record by Swiftcurrent Partners, L.P., Swiftcurrent Offshore Master Ltd. and Bridger Healthcare Ltd. Bridger Management LLC is the investment adviser to Swiftcurrent Partners L.P., Swiftcurrent Offshore Master Ltd., and Bridger Healthcare Ltd., and as such, may be deemed to share beneficial ownership of the Shares. Roberto Mignone is the manager of Bridger Management, LLC. F3 · ownership.direct: Each reporting person and entity named herein disclaims beneficial ownership of the reported securities except to the extent of his or its pecuniary interest therein and this report shall not be deemed an admission that the reporting person or any entity named herein is the beneficial owner of the securities for purposes of Section 16, or for any other purpose. F2 · ownership.nature: The shares of Common Stock, $.0001 par value per share (the "Shares"), reported herein as indirectly beneficially owned by the Reporting Persons are held of record by Swiftcurrent Partners, L.P., Swiftcurrent Offshore Master Ltd. and Bridger Healthcare Ltd. Bridger Management LLC is the investment adviser to Swiftcurrent Partners L.P., Swiftcurrent Offshore Master Ltd., and Bridger Healthcare Ltd., and as such, may be deemed to share beneficial ownership of the Shares. Roberto Mignone is the manager of Bridger Management, LLC. F3 · ownership.nature: Each reporting person and entity named herein disclaims beneficial ownership of the reported securities except to the extent of his or its pecuniary interest therein and this report shall not be deemed an admission that the reporting person or any entity named herein is the beneficial owner of the securities for purposes of Section 16, or for any other purpose. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.